139 related articles for article (PubMed ID: 31493939)
1. Upregulation of the long non-coding RNA FAM83H-AS1 in gastric cancer and its clinical significance.
Da J; Liu P; Wang R; Bu L
Pathol Res Pract; 2019 Oct; 215(10):152616. PubMed ID: 31493939
[TBL] [Abstract][Full Text] [Related]
2. Serum LncRNA-ATB and FAM83H-AS1 as diagnostic/prognostic non-invasive biomarkers for breast cancer.
El-Ashmawy NE; Hussien FZ; El-Feky OA; Hamouda SM; Al-Ashmawy GM
Life Sci; 2020 Oct; 259():118193. PubMed ID: 32763293
[TBL] [Abstract][Full Text] [Related]
3. LncRNA FAM83H-AS1 contributes to the radioresistance, proliferation, and metastasis in ovarian cancer through stabilizing HuR protein.
Dou Q; Xu Y; Zhu Y; Hu Y; Yan Y; Yan H
Eur J Pharmacol; 2019 Jun; 852():134-141. PubMed ID: 30831080
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of lncRNA FAM83H-AS1 in ovarian cancer.
Gong YB; Zou YF
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4656-4662. PubMed ID: 31210291
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA ZEB1-AS1 is associated with poor prognosis in gastric cancer and promotes cancer cell metastasis.
Liu XJ; Li SL; Li JS; Lu H; Yin LL; Zheng WF; Wang WC
Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2624-2630. PubMed ID: 29771411
[TBL] [Abstract][Full Text] [Related]
6. Promoting roles of long non-coding RNA FAM83H-AS1 in bladder cancer growth, metastasis, and angiogenesis through the c-Myc-mediated ULK3 upregulation.
Liu B; Gao W; Sun W; Li L; Wang C; Yang X; Liu J; Guo Y
Cell Cycle; 2020 Dec; 19(24):3546-3562. PubMed ID: 33289601
[TBL] [Abstract][Full Text] [Related]
7. Silence of FAM83H-AS1 promotes chemosensitivity of gastric cancer through Wnt/β-catenin signaling pathway.
Wang B; Guan G; Zhao D
Biomed Pharmacother; 2020 May; 125():109961. PubMed ID: 32028241
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of FAM83H-AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer.
Zhang J; Feng S; Su W; Bai S; Xiao L; Wang L; Thomas DG; Lin J; Reddy RM; Carrott PW; Lynch WR; Chang AC; Beer DG; Guo YM; Chen G
Sci Rep; 2017 Feb; 7():42819. PubMed ID: 28198463
[TBL] [Abstract][Full Text] [Related]
9. FAM83H-AS1 is upregulated and predicts poor prognosis in colon cancer.
Yang L; Cui J; Wang Y; Tan J
Biomed Pharmacother; 2019 Oct; 118():109342. PubMed ID: 31545230
[TBL] [Abstract][Full Text] [Related]
10. LncRNA FAM83H-AS1 Contributes to the Radio-resistance and Proliferation in Liver Cancer through Stability FAM83H Protein.
Jiang X; Lan Y; Zhang Y; Dong Y; Song T
Recent Pat Anticancer Drug Discov; 2024; 19(3):316-327. PubMed ID: 37132310
[TBL] [Abstract][Full Text] [Related]
11. LncRNA CADM1-AS1 serves as a new prognostic biomarker for gastric cancer.
Shi XY; Sun YZ; Li M; Li HY
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):232-238. PubMed ID: 31389606
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA FAM83H-AS1 acts as a potential oncogenic driver in human ovarian cancer.
Yuan X; Huang Y; Guo M; Hu X; Li P
J Ovarian Res; 2021 Jan; 14(1):6. PubMed ID: 33413565
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA ZEB2-AS1 expression is associated with disease progression and predicts outcome in gastric cancer patients.
Xu C; Cui H; Li H; Wu Y; An H; Guo C
J BUON; 2019; 24(2):663-671. PubMed ID: 31128021
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding RNA FAM83H-AS1 exerts an oncogenic role in glioma through epigenetically silencing CDKN1A (p21).
Bi YY; Shen G; Quan Y; Jiang W; Xu F
J Cell Physiol; 2018 Nov; 233(11):8896-8907. PubMed ID: 29870057
[TBL] [Abstract][Full Text] [Related]
15. Circulating long non-coding RNA AFAP1-AS1 is a potential diagnostic biomarker for non-small cell lung cancer.
Li W; Li N; Kang X; Shi K
Clin Chim Acta; 2017 Dec; 475():152-156. PubMed ID: 29080690
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA FEZF1-AS1 indicates a poor prognosis of gastric cancer and promotes tumorigenesis via activation of Wnt signaling pathway.
Wu X; Zhang P; Zhu H; Li S; Chen X; Shi L
Biomed Pharmacother; 2017 Dec; 96():1103-1108. PubMed ID: 29239821
[TBL] [Abstract][Full Text] [Related]
17. Aberrantly upregulated FAM83H-AS1 facilitates malignant progression of esophageal squamous cell carcinoma.
Bu L; Wang R; Liu P; Da J
Oncol Lett; 2020 Dec; 20(6):368. PubMed ID: 33154766
[TBL] [Abstract][Full Text] [Related]
18. Increased lncRNA AFAP1-AS1 expression predicts poor prognosis and promotes malignant phenotypes in gastric cancer.
Feng Y; Zhang Q; Wang J; Liu P
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(17):3842-3849. PubMed ID: 28975981
[TBL] [Abstract][Full Text] [Related]
19. FAM83H-AS1 is associated with clinical progression and modulates cell proliferation, migration, and invasion in bladder cancer.
Shan H; Yang Y; Zhu X; Han X; Zhang P; Zhang X
J Cell Biochem; 2019 Mar; 120(3):4687-4693. PubMed ID: 30537032
[TBL] [Abstract][Full Text] [Related]
20. The lncRNA MACC1-AS1 promotes gastric cancer cell metabolic plasticity via AMPK/Lin28 mediated mRNA stability of MACC1.
Zhao Y; Liu Y; Lin L; Huang Q; He W; Zhang S; Dong S; Wen Z; Rao J; Liao W; Shi M
Mol Cancer; 2018 Mar; 17(1):69. PubMed ID: 29510730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
